Regeneron Pharmaceuticals develops, manufactures, and sells medicines for various diseases worldwide. Products include EYLEA for eye conditions, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for hypercholesterolemia and cardiovascular disease, REGEN-COV for COVID-19, Kevzara for rheumatoid arthritis, Inmazeb for ebolavirus infection, ARCALYST for cryopyrin-associated periodic syndromes, and ZALTRAP for metastatic colorectal cancer.
| Indicator | Value |
|---|---|
| PER | 14.3 |
| EV/EBITDA | 12.1 |
| Price/Free Cash Flow' | 17.8 |
| ROIC | 13.8% |
| Net Debt/EBITDA | 0.0 |